




Instance: composition-en-e3c8c4151821eafa3b8558a4b1967125
InstanceOf: CompositionUvEpi
Title: "Composition for evista Package Leaflet"
Description:  "Composition for evista Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpe3c8c4151821eafa3b8558a4b1967125)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - evista"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Evista is and what it is used for </li>
<li>What you need to know before you take Evista </li>
<li>How to take Evista </li>
<li>Possible side effects </li>
<li>How to store Evista </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What evista is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What evista is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Evista contains the active substance raloxifene hydrochloride. </p>
<p>Evista is used to treat and prevent osteoporosis in postmenopausal women. Evista reduces the risk of 
vertebral fractures in women with postmenopausal osteoporosis. A reduction in the risk of hip 
fractures has not been shown. </p>
<p>How Evista works: </p>
<p>Evista belongs to a group of non-hormonal medicines called Selective Oestrogen Receptor Modulators 
(SERMs). When a woman reaches the menopause, the level of the female sex hormone oestrogen goes 
down. Evista mimics some of the helpful effects of oestrogen after the menopause.  </p>
<p>Osteoporosis is a disease that causes your bones to become thin and fragile - this disease is especially 
common in women after the menopause. Although it may have no symptoms at first, osteoporosis 
makes you more likely to break bones, especially in your spine, hips and wrists and may cause back 
pain, loss of height and a curved back. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take evista"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take evista"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Evista: </p>
<ul>
<li>If you are being treated or have been treated for blood clots in the legs (deep vein thrombosis), 
in the lungs (pulmonary embolism) or in the eyes (retinal vein thrombosis). </li>
<li>If you are allergic (hypersensitive) to raloxifene or any of the other ingredients of this medicine 
(listed in section 6). </li>
<li>If there is still a possibility that you can get pregnant, Evista could harm your unborn child. </li>
<li>If you have liver disease (examples of liver disease include cirrhosis, mild hepatic impairment 
or cholestatic jaundice). </li>
<li>If you have severe kidney problems. </li>
<li>If you have any unexplained vaginal bleeding. This must be investigated by your doctor. </li>
<li>If you have active uterine cancer, as there is insufficient experience of Evista use in women with 
this disease. </li>
</ul>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before you take Evista. </p>
<ul>
<li>If you are immobilised for some time such as being wheel-chair bound, needing to be admitted 
to a hospital or having to stay in bed while recovering from an operation or an unexpected 
illness as these may increase your risk of blood clots (deep vein thrombosis, pulmonary 
embolism or retinal vein thrombosis). </li>
<li>If you have had a cerebrovascular accident (e.g. stroke), or if your doctor has told you that you 
are at high risk of having one. </li>
<li>If you have liver disease </li>
<li>If you are suffering from breast cancer, as there is insufficient experience of Evista use in 
women with this disease. </li>
<li>If you are receiving oral oestrogen therapy. </li>
</ul>
<p>It is unlikely that Evista will cause vaginal bleeding. So any vaginal bleeding while you take Evista is 
unexpected. You should have this investigated by your doctor. </p>
<p>Evista does not treat postmenopausal symptoms, such as hot flushes. </p>
<p>Evista lowers total cholesterol and LDL ("bad") cholesterol. In general, it does not change 
triglycerides or HDL ("good") cholesterol. However, if you have taken oestrogen in the past and had 
extreme elevations in triglycerides, you should talk to your doctor before taking Evista.   </p>
<p>Evista contains lactose 
If you have been told by your doctor that you have an intolerance to lactose, a type of sugar, contact 
your doctor before taking this medicinal product. </p>
<p>Other medicines and Evista 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines, including medicines obtained without a prescription. </p>
<p>If you are taking digitalis medicines for your heart or anticoagulants like warfarin to thin your blood, 
your doctor may need to adjust your dose of these medicines. </p>
<p>Tell your doctor if you are taking cholestyramine which is mainly used as lipid-lowering medicine, 
because Evista may not work as well. </p>
<p>Pregnancy and breast-feeding 
Evista is for use only by postmenopausal women and must not be taken by women who could still 
have a baby. Evista could harm your unborn child. 
Do not take Evista if you are breast-feeding as it might be excreted in mother's milk. </p>
<p>Driving and using machines 
Evista has no or negligible effects on driving or using machines. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take evista"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take evista"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or 
pharmacist if you are not sure. </p>
<p>The dose is one tablet a day. It does not matter what time of day you take your tablet but taking the 
tablet at the same time each day will help you remember to take it. You may take it with or without 
food. </p>
<p>The tablets are for oral use. 
Swallow the tablet whole. If you wish you may take a glass of water with it. Do not break or crush the 
tablet before taking it. A broken or crushed tablet may taste bad and there is a possibility that you will 
receive an incorrect dose. </p>
<p>Your doctor will tell you how long you should continue to take Evista. The doctor may also advise 
you to take calcium and vitamin D supplements. </p>
<p>If you take more Evista than you should 
Tell your doctor or pharmacist. If you take more Evista than you should you could have leg cramps 
and dizziness. </p>
<p>If you forget to take Evista 
Take a tablet as soon as you remember and then continue as before. Do not take a double dose to make 
up for a forgotten tablet dose. </p>
<p>If you stop taking Evista 
You should talk to your doctor first. 
It is important that you continue taking Evista for as long as your doctor prescribes the medicine. 
Evista can treat or prevent your osteoporosis only if you continue to take the tablets. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects although not everybody gets them. The 
majority of side effects seen with Evista have been mild. </p>
<p>The most common side effects (affects more than 1 user in 10) are:<br />
* Hot flushes (vasodilatation) 
* Flu syndrome 
* Gastrointestinal symptoms such as nausea, vomiting, abdominal pain and stomach upset 
* Increased blood pressure </p>
<p>Common side effects (affects 1 to 10 users in 100) are: 
* Headache including migraine 
* Leg cramps<br />
<em> Swelling of hands, feet and legs (peripheral oedema)<br />
</em> Gallstones 
* Rash 
* Mild breast symptoms such as pain, enlargement and tenderness </p>
<p>Uncommon side effects (affects 1 to 10 users in 1000) are: 
* Increased risk of blood clots in the legs (deep vein thrombosis) 
* Increased risk of blood clots in the lungs (pulmonary embolism) 
* Increased risk of blood clots in the eyes (retinal vein thrombosis) 
* Skin around the vein is red and painful (superficial vein thrombophlebitis) 
* Blood clot in an artery (for example stroke, including an increased risk of dying from stroke)<br />
* Decrease in the number of the platelets in the blood  </p>
<p>In rare cases, blood levels of liver enzymes may increase during treatment with Evista.  </p>
<p>Reporting of side effects 
If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store evista"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store evista"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use after the expiry date which is stated on the pack after EXP. The expiry date refers to the 
last day of the month. </p>
<p>Store in the original package. Do not freeze.  </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Evista contains 
- The active substance is raloxifene hydrochloride. Each tablet contains 60 mg of raloxifene 
hydrochloride, which is equivalent to 56 mg raloxifene. </p>
<ul>
<li>The other ingredients are: </li>
</ul>
<p>Tablet Core: Povidone, polysorbate 80, anhydrous lactose, lactose monohydrate, crospovidone, 
magnesium stearate.<br />
Tablet coating: Titanium dioxide (E 171), polysorbate 80, hypromellose, macrogol 400. What Evista looks like and contents of the pack 
Evista are white, oval, film coated tablets. They are packed in blisters or in plastic bottles. The blister 
boxes contain 14, 28 or 84 tablets. The bottles contain 100 tablets. Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
SUBSTIPHARM, 24 rue Erlanger, 75016 Paris, France. </p>
<p>Manufacturer 
- INPHARMASCI, ZI N 2 de Prouvy-Rouvignies, 1 rue de Nungesser, 59121 Prouvy, France. </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/ Belgien 
SUBSTIPHARM 
T l/Tel: 080077Lietuva 
SUBSTIPHARM 
Tel: +33 1 43 18 13 <br />
SUBSTIPHARM 
 .: +33 1 43 18 13 Luxembourg/Luxemburg 
SUBSTIPHARM 
T l/Tel: 80024 esk  republika 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Magyarorsz g 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Danmark 
SUBSTIPHARM 
Tlf: +33 1 43 18 13 Malta 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Deutschland 
SUBSTIPHARM 
Tel: 08001801Nederland 
SUBSTIPHARM 
Tel: 08000228Eesti 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Norge 
SUBSTIPHARM 
Tlf: +33 1 43 18 13   </p>
<p>: +30 210 620 8 sterreich 
SUBSTIPHARM 
Tel: 0800298Espa a 
SUBSTIPHARM 
Tel: 900993Polska 
SUBSTIPHARM 
Tel: +33 1 43 18 13 France 
SUBSTIPHARM 
T l: +33 1 43 18 13 Portugal 
SUBSTIPHARM 
Tel: 800833Hrvatska 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Rom nia 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Ireland 
SUBSTIPHARM 
Tel: 1800300Slovenija 
SUBSTIPHARM 
Tel: +33 1 43 18 13  sland 
SUBSTIPHARM 
Simi: +33 1 43 18 13 Slovensk  republika 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Italia 
SUBSTIPHARM 
Tel: 800780Suomi/Finland 
SUBSTIPHARM 
Puh./Tel: +33 1 43 18 13 <br />
SUBSTIPHARM 
 : +33 1 43 18 13 Sverige 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Latvija 
SUBSTIPHARM 
Tel.: +33 1 43 18 13 United Kingdom (Northern Ireland) 
SUBSTIPHARM 
Tel: +33 1 43 18 13 This leaflet was last revised in month YYYY. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency (EMA) web 
site: http://www.ema.europa.eu </p>         </div>"""      



Instance: composition-da-e3c8c4151821eafa3b8558a4b1967125
InstanceOf: CompositionUvEpi
Title: "Composition for evista Package Leaflet"
Description:  "Composition for evista Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpe3c8c4151821eafa3b8558a4b1967125)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - evista"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal De vide, før De begynder at tage Evista 
3. Sådan skal De tage Evista 
4. Bivirkninger<br />
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What evista is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What evista is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Evista indeholder det aktive indholdsstof raloxifenhydrochlorid. </p>
<p>Evista bruges til at behandle og forebygge knogleskørhed hos kvinder, der har passeret overgangs-
alderen (postmenopausal osteoporose). Evista nedsætter risikoen for brud på rygsøjlen hos kvinder 
med knogleskørhed efter overgangsalderen. En nedsat risiko for hoftebrud er ikke set. </p>
<p>Virkning: </p>
<p>Evista tilhører en gruppe af ikke-hormonale lægemidler, som kaldes selektive østrogen-receptor 
modulatorer (SERM). Når en kvinde kommer i overgangsalderen, falder produktionen af det 
kvindelige kønshormon, østrogen. Evista efterligner nogle af de gavnlige virkninger af østrogen efter 
overgangsalderen.  </p>
<p>Knogleskørhed er en sygdom, som gør Deres knogler tynde og skrøbelige. Denne sygdom er især 
almindelig hos kvinder efter overgangsalderen. Selvom knogleskørhed i begyndelsen ikke giver 
symptomer, kan den øge risikoen for, at De brækker Deres knogler, specielt rygsøjlen, hofterne og 
håndleddene. Knogleskørhed kan også medføre, at De får rygsmerter, bliver lavere og får en rund ryg. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take evista"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take evista"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Evista: </p>
<ul>
<li>
<p>hvis De bliver eller har været behandlet for blodpropper (blodprop i benene, blodprop i lungerne 
eller blodprop i øjets nethinde). </p>
</li>
<li>
<p>hvis De er allergisk (overfølsom) over for raloxifen eller et af de øvrige indholdsstoffer i dette 
lægemiddel (angivet i punkt 6).  </p>
</li>
<li>
<p>hvis De stadigvæk har mulighed for at blive gravid. Evista kan skade det ufødte barn. </p>
</li>
<li>
<p>hvis De har en leversygdom (eksempler på leversygdomme omfatter skrumpelever, let nedsat 
leverfunktion og gulsot på grund af afløbshindring). </p>
</li>
<li>
<p>hvis De har svære problemer med nyrerne. </p>
</li>
<li>
<p>hvis De af ukendt årsag har blødning fra underlivet. Dette skal undersøges af Deres læge. </p>
</li>
<li>
<p>hvis De har aktiv livmoderkræft, da der er utilstrækkelig erfaring med Evista hos kvinder med 
denne sygdom. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før De taget Evista </p>
<ul>
<li>
<p>hvis De ikke kan bevæge Dem normalt i nogen tid, fordi De sidder i kørestol, skal på hospitalet 
eller ligge i sengen efter en operation eller en uventet sygdom, da dette kan øge Deres risiko for 
blodpropper (blodprop i benene, blodprop i lungerne eller blodprop i øjets nethinde). </p>
</li>
<li>
<p>hvis De har haft et slagtilfælde, eller hvis Deres læge har fortalt Dem, at De har høj risiko for at 
få et. </p>
</li>
<li>
<p>hvis De har en leversygdom </p>
</li>
<li>
<p>hvis De har brystkræft, idet der er begrænset erfaring med brug af Evista hos kvinder med denne 
sygdom. </p>
</li>
<li>
<p>hvis De tager hormontabletter med østrogen. </p>
</li>
</ul>
<p>Det er usandsynligt, at Evista vil give blødning fra underlivet. Enhver form for blødning fra underlivet, 
mens De tager Evista, er derfor uventet. De bør have dette undersøgt af Deres læge. </p>
<p>Evista kan ikke lindre symptomer, såsom hedestigninger, som opstår i forbindelse med overgangs-
alderen. </p>
<p>Evista sænker det samlede kolesterol og LDL ("farligt") kolesterol. Generelt set påvirker det hverken 
triglycerider eller HDL ("sundt") kolesterol. Hvis De imidlertid tidligere har taget østrogen, og De har 
haft voldsomme stigninger i blodets triglycerider, bør De tale med Deres læge, før De tager Evista.  </p>
<p>Evista indeholder lactose 
Kontakt lægen, før De tager denne medicin, hvis lægen har fortalt Dem, at De ikke tåler visse 
sukkerarter,  </p>
<p>Brug af anden medicin sammen med Evista 
Fortæl altid lægen eller apotekspersonalet, hvis De bruger anden medicin eller har gjort det for nylig. 
Dette gælder også medicin, som ikke er købt på recept, f.eks. naturlægemidler, og vitaminer og 
mineraler. </p>
<p>Hvis De tager digitalispræparater på grund af Deres hjerte eller antikoagulantia for at fortynde Deres 
blod (f.eks. warfarin), er Deres læge måske nødt til at justere Deres dosis af denne medicin. </p>
<p>Fortæl det til Deres læge, hvis De får colestyramin, der hovedsageligt anvendes som lipidsænkede 
medicin, da Evista muligvis ikke virker så godt sammen med colestyramin. </p>
<p>Graviditet og amning 
Evista må kun anvendes af kvinder, der har passeret overgangsalderen og må ikke anvendes af 
kvinder, der stadig kan få børn. Evista kunne skade det ufødte barn. 
Anvend ikke Evista hvis De ammer, da det muligvis udskilles i modermælk. </p>
<p>Trafik- og arbejdssikkerhed 
Evista påvirker ikke eller kun i ubetydelig grad evnen til at køre bil eller betjene maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take evista"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take evista"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Doseringen er én tablet daglig. Det er lige meget, hvornår på dagen De tager din tablet, men hvis De 
tager tabletten på samme tidspunkt hver dag, er det nemmere at huske. De kan tage tabletten med eller 
uden mad. </p>
<p>Tabletterne er til oral anvendelse. 
Synk tabletten hel. De skal synke tabletten med et glas vand eller anden væske. Del eller knus ikke 
tabletten inden indtagelse. En delt eller knust tablet kan smage dårligt, og der er risiko for, at De får en 
forkert dosis. </p>
<p>Deres læge vil fortælle Dem, hvor længe De skal tage Evista. Deres læge vil måske også råde Dem til 
at tage kalk- eller vitamin D-tilskud. </p>
<p>Hvis De har taget for mange Evista tabletter<br />
Kontakt lægen eller apoteket.  De kan få kramper i benene eller blive svimmel, hvis De har taget flere 
Evista tabletter, end De skal. </p>
<p>Hvis De har glemt at tage Evista<br />
Tag en tablet lige så snart, De husker det, og fortsæt derefter som før. De må ikke tage en dobbeltdosis 
som erstatning for den glemte. </p>
<p>Hvis De holder op med at tage Evista 
De skal først tale med Deres læge om det. 
Det er vigtigt, at De fortsætter med at tage Evista i så lang tid, som lægen har ordineret medicinen. 
Evista kan kun behandle eller forebygge knogleskørhed, hvis De fortsætter med at tage tabletterne. </p>
<p>Spørg lægen eller på apotekspersonalet, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin givebivirkninger, men ikke alle får bivirkninger. 
Størstedelen af de bivirkninger, som er set med Evista, har været lette. </p>
<p>Meget almindelig (kan ramme mere end 1 af 10 patienter): </p>
<ul>
<li>
<p>Hedeture </p>
</li>
<li>
<p>Influenzasymptomer </p>
</li>
<li>
<p>Gener fra mave-tarmkanalen såsom kvalme, opkastning, mavesmerter, fordøjelsesbesvær </p>
</li>
<li>
<p>Forhøjet blodtryk </p>
</li>
</ul>
<p>Almindelig (kan ramme 1 til 10 ud af 100 patienter): </p>
<ul>
<li>
<p>Hovedpine herunder migræne </p>
</li>
<li>
<p>Kramper i benene </p>
</li>
<li>
<p>Hævede hænder, fødder og ben (perifer væskeophobning): </p>
</li>
<li>
<p>Galdesten </p>
</li>
<li>
<p>Hududslæt </p>
</li>
<li>
<p>Lette symptomer i brystet, såsom smerter, hævelse, ømhed </p>
</li>
</ul>
<p>Ikke almindelig (kan ramme 1 til 10 ud af 1.000 patienter): </p>
<ul>
<li>
<p>Øget risiko for blodpropper i benene (dyb venetrombose) </p>
</li>
<li>
<p>Øget risiko for blodpropper i lungerne (lungeemboli) </p>
</li>
<li>
<p>Øget risiko for blodproper i øjet (nethinde venetrombose) </p>
</li>
<li>
<p>Rød og smertende hud omkring en vene (årebetændelse med blodprop i huden) </p>
</li>
<li>
<p>Blodprop i en arterie (f.eks. slagtilfælde samt en øget risiko for at dø af et slagtilfælde) </p>
</li>
<li>
<p>Færre blodplader i blodet </p>
</li>
</ul>
<p>I sjældne tilfælde kan blodets indhold af leverenzymer stige under behandling med Evista. </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført 
i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store evista"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store evista"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidletutilgængeligt for børn. </p>
<p>Brug ikke Evista efter den udløbsdato, der står på pakningen. Udløbsdatoen er den sidste dag i den 
nævnte måned. </p>
<p>Opbevares i originalemballagen. Må ikke fryses.  </p>
<p>Spørg på apoteket, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Evista indeholder:</p>
<ul>
<li>
<p>Aktivt stof: raloxifenhydrochlorid. Hver tablet indeholder 60 mg raloxifenhydrochlorid, hvilket 
svarer til 56 mg raloxifen. </p>
</li>
<li>
<p>Øvrige indholdsstoffer:  </p>
</li>
</ul>
<p>Tabletkerne: Povidon, polysorbat 80, vandfri lactose, lactosemonohydrat, crospovidon, 
magnesiumstearat. </p>
<p>Tabletovertræk: Titandioxid (E 171), polysorbat 80, hypromellose, macrogol 400. Udseende og pakningsstørrelser 
Evista er hvide, ovale tabletter med et filmovertræk. De fås i blisterpakninger eller i tabletglas af 
plastic. Blisterpakningerne indeholder 14, 28 eller 84 tabletter. Tabletglassene indeholder tabletter. Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaveren af markedsføringstilladelsen 
SUBSTIPHARM, 24 rue Erlanger, 75016 Paris, Frankrig. </p>
<p>Fremstiller 
INPHARMASCI, ZI N°2 de Prouvy-Rouvignies, 1 rue de Nungesser, 59121 Prouvy, Frankrig. </p>
<p>Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/ Belgien 
SUBSTIPHARM 
Tél/Tel: 080077Lietuva 
SUBSTIPHARM 
Tel: +33 1 43 18 13 България 
SUBSTIPHARM 
Тел.: +33 1 43 18 13 Luxembourg/Luxemburg 
SUBSTIPHARM 
Tél/Tel: 80024Česká republika 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Magyarország 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Danmark 
SUBSTIPHARM 
Tlf: +33 1 43 18 13 Malta 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Deutschland 
SUBSTIPHARM 
Tel: 08001801Nederland 
SUBSTIPHARM 
Tel: 08000228Eesti 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Norge 
SUBSTIPHARM 
Tlf: +33 1 43 18 13 Ελλάδα 
ΦΑΡΜΑΣΕΡΒ ΕΛΛΑΣ 
Τηλ: +30 210 620 8Österreich 
SUBSTIPHARM 
Tel: 0800298España 
SUBSTIPHARM 
Tel: 900993Polska 
SUBSTIPHARM 
Tel: +33 1 43 18 13 France 
SUBSTIPHARM 
Tél: +33 1 43 18 13 Portugal 
SUBSTIPHARM 
Tel: 800833Hrvatska 
SUBSTIPHARM 
Tel: +33 1 43 18 13 România 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Ireland 
SUBSTIPHARM 
Tel: 1800300Slovenija 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Ísland 
SUBSTIPHARM 
Simi: +33 1 43 18 13 Slovenská republika 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Italia 
SUBSTIPHARM 
Tel: 800780Suomi/Finland 
SUBSTIPHARM 
Puh./Tel: +33 1 43 18 13 Κύπρος 
SUBSTIPHARM 
Τηλ: +33 1 43 18 13 Sverige 
SUBSTIPHARM 
Tel: +33 1 43 18 13 Latvija 
SUBSTIPHARM 
Tel.: +33 1 43 18 13 United Kingdom (Northern Ireland) 
SUBSTIPHARM 
Tel: +33 1 43 18 13<br />
Denne indlægsseddel blev senest ændret: måned ÅÅÅÅ  </p>
<p>De kan finde yderligere oplysninger om Evista på Det Europæiske Lægemiddelagenturs hjemmeside 
http://www.ema.europa.eu.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-e3c8c4151821eafa3b8558a4b1967125
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for evista Package Leaflet for language en"
Description: "ePI document Bundle for evista Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-e3c8c4151821eafa3b8558a4b1967125"
* entry[0].resource = composition-en-e3c8c4151821eafa3b8558a4b1967125

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe3c8c4151821eafa3b8558a4b1967125"
* entry[=].resource = mpe3c8c4151821eafa3b8558a4b1967125
                            
                    
Instance: bundlepackageleaflet-da-e3c8c4151821eafa3b8558a4b1967125
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for evista Package Leaflet for language da"
Description: "ePI document Bundle for evista Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-e3c8c4151821eafa3b8558a4b1967125"
* entry[0].resource = composition-da-e3c8c4151821eafa3b8558a4b1967125

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe3c8c4151821eafa3b8558a4b1967125"
* entry[=].resource = mpe3c8c4151821eafa3b8558a4b1967125
                            
                    



Instance: mpe3c8c4151821eafa3b8558a4b1967125
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Evista 60 mg film coated tablets"
Description: "Evista 60 mg film coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/98/073/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Evista 60 mg film coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: e3c8c4151821eafa3b8558a4b1967125ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "evista"

* status = #current
* mode = #working

* title = "List of all ePIs associated with evista"

* subject = Reference(mpe3c8c4151821eafa3b8558a4b1967125)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#evista "evista"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-e3c8c4151821eafa3b8558a4b1967125) // evista en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-e3c8c4151821eafa3b8558a4b1967125) // evista da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-e3c8c4151821eafa3b8558a4b1967125
InstanceOf: List

* insert e3c8c4151821eafa3b8558a4b1967125ListRuleset
    